WIT 2001
Alternative Names: WIT-2001Latest Information Update: 13 Apr 2023
At a glance
- Originator Whanin Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 13 Apr 2023 Phase-I clinical trials in Parkinson's disease in South Korea (unspecified route) before April 2023 (Whanin Pharmaceutical pipeline, April 2023)
- 16 Feb 2021 WIT 2001 is available for licensing as of 16 Feb 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor#
- 16 Feb 2021 Early research in Parkinson's disease in South Korea (unspecified route) before February 2021 (Whanin Pharmaceutical pipeline, February 2021)